Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
116
resultados
Última actualización
16/10/2026 [07:20:00]
Resumen de: CN109415772A
Provided herein are methods and compositions for detecting Salmonella Typhimurium in a sample.
Resumen de: US20260306554A1
0000 The present disclosure relates to a recombinant expression vector for secretion of an IFN-β protein and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising an flgM gene, an IFN-β gene, and an flhDC gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain as an active ingredient.
Resumen de: US20260306602A1
Provided herein are vaccine compositions comprising Salmonella antigens conjugated to a capsid, wherein said capsid comprises wild type or native sequence, or said capsid may comprise at least one mutation, such as a non-natural mutation; such compositions being useful in the treatment and prevention of a Salmonella infection (salmonellosis), gastroenteritis, typhoid fever, and/or paratyphoid fever; and may be effective against multiple strains of Salmonella.
Resumen de: US20260308603A1
Provided are a recombinant expression vector for secretion of CAT protein and an E. coli strain transformed with the vector. Provided are a recombinant expression vector including a flgM gene, a CAT gene, and a flhDC gene, an E. coli strain transformed with the vector, and a pharmaceutical composition for treating cancer, including the E. coli strain as an active ingredient.
Resumen de: US20260309706A1
A method for pathogen detection is also disclosed which includes (i) operating a micropump forcing a first fluid hosting a pathogen-selective antibody from a source to a destination, defining a target, via a microfluidic channel, (ii) operating the micropump to thereby force a second fluid potentially hosting the selective pathogen from the source to the destination, obtaining a signal from the destination indicating a mass change; (iii) comparing the mass change to a predetermined threshold to indicate conditional presence of the pathogen and concentration of the pathogen, (iv) operating the micropump forcing a third fluid hosting a pathogen-selective photoluminescent label from the source to the destination, (v) activating a light excitation subsystem, (vi) capturing images from the target; and (vii) analyzing the images to determine presence of the label thus double-confirming a) presence of the pathogen, and b) concentration of the pathogen.
Resumen de: WO2026208522A1
A microbial antibodyomics technology-based system and method for directed isolation of intestinal bacteria. Said system comprises a negative pressure driving mechanism, a filtration and impurity removal device (100) used for performing filtration and impurity removal treatment on a feces sample, a harmful bacterium adsorption assembly (210) used for removing harmful bacteria in a microbial mixture liquid, a beneficial bacterium enrichment assembly (220) used for performing positive enrichment treatment on beneficial bacteria in the microbial mixture liquid, a beneficial bacterium dissociation assembly (234) used for performing dissociation on beneficial bacterium-coupled bodies, and a beneficial bacterium collection bottle (240) used for collecting beneficial bacteria. The negative pressure driving mechanism is used for enabling the beneficial bacteria in the feces sample to automatically enter the beneficial bacterium collection bottle (240) after sequentially passing through the filtration and impurity removal device (100), the beneficial bacterium enrichment assembly (220) and the beneficial bacterium dissociation assembly (234). Therefore, directly and selectively screening target beneficial bacteria from feces samples is achieved, and the requirements of accurate transplantation of intestinal flora and accurate treatment of specifically related intestinal diseases in the future can be met.
Resumen de: US20260301973A1
Certain pathogens are known to cause infection in humans or other living hosts. However, harmful pathogens may have thousands of distinct strains or serovars, only a fraction of which may cause a severe or life-threatening infection. Timely identification of strains which are most likely to cause serious infections is problematic. A system and a method are disclosed which provide a diagnostic protocol for identifying virulence groups in one or more pathogens of interest based on genomic features and/or identifying pathogenic markers of higher virulence in hazardous pathogens such as Salmonella enterica which may be used in combination with pathogen surveillance data to optimize the identification of pathogens of public risk and health concern so that the most effective interventions may be selected and applied in a timely manner.
Resumen de: US20260298925A1
Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.
Resumen de: EP4814110A1
0001 Provided are a preparation method and application of cryo-shocked monocytes or macrophages loaded with attenuated Salmonella. The method comprises loading engineered attenuated Salmonella into monocytes or macrophages, followed by cryo-shock treatment of monocytes or macrophages loaded with the strain using liquid nitrogen. The method for preparing the cryo-shocked immune cells loaded with the strain is simple and easy to operate, and solves the source problem of the monocytes or macrophages loaded with engineered attenuated Salmonella is solved, thus having good application prospects. This strategy improves the biosafety of bacteria-based anti-tumor therapy by avoiding bacterial exposure and heterologous stimulation; and high intratumoral strain titer promotes an anti-tumor immune response, thereby achieving stronger anti-tumor efficacy.
Resumen de: WO2025037284A2
A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.
Resumen de: CN122811060A
本发明公开了一种重组肠炎沙门菌及其构建方法和应用。本发明通过在肠炎沙门菌同时敲除msbB基因和purL基因，获得减毒的重组肠炎沙门菌，并应用于减毒活疫苗的制备。本发明公开的双基因同时缺失的肠炎沙门菌减毒株毒力较野生型肠炎沙门菌显著下降，在宿主体内定殖时间明显缩短，接种后鸡只无不良反应，对强毒力肠炎沙门菌提供良好的保护作用，可有效清除强毒力菌株感染，对雏鸡提供坚实的免疫保护效果。
Resumen de: WO2026194530A1
The present invention belongs to the field of biomedicine. Provided are a composition for treating tumors using attenuated Salmonella and an immune checkpoint inhibitor, and a method for treating tumors. In the present invention, an anti-tumor immune response is activated by means of the combined use of attenuated Salmonella and an immune checkpoint inhibitor, which synergistically improves the inhibitory effect on tumor cells. The present invention exhibits excellent therapeutic effects against malignant tumors for which effective control means are currently lacking, and has broad application prospects.
Resumen de: US20260284172A1
Disclosed are compositions comprising a fusion polypeptide comprising i) a fusion of a needle tip protein or an antigenic fragment thereof and/or a translocator protein or an antigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria and ii) the A1 subunit of the labile toxin (LTA1) from enterotoxigenic Escherichia coli or cholera toxin. and methods of their use.
Resumen de: EP4810124A2
A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.
Resumen de: GB2645265A
Provided is a method for testing the in-vitro bactericidal function of a typhoid vaccine immune serum, comprising: testing the in-vitro bactericidal function of a typhoid vaccine immune serum against Salmonella typhi bacteria by means of an opsonophagocytic killing assay, wherein when the phagocytic killing step of the opsonophagocytic killing assay is completed, the Salmonella typhi bacteria having undergone the phagocytic killing step are cultured at the pH of 7.5-9.5. The opsonophagocytic killing assay is applied to Gram-negative Salmonella Typhi bacteria for the first time, and the in-vitro bactericidal levels of typhoid vaccine immune serums are effectively and accurately evaluated.
Resumen de: WO2024122796A1
The present invention relates to a pharmaceutical composition containing aspartic acid as an active ingredient for the prevention or treatment of sepsis and sepsis-related diseases. Containing aspartic acid as an active ingredient, the composition according to an aspect can achieve the effect of inducing the secretion of inflammatory cytokines during immune tolerance or suppression. Moreover, this effect can increase the survival rate of sepsis animal models, compared to antibiotic-administered groups, whereby the composition can be advantageously applied to the prevention and/or treatment of sepsis or systemic inflammatory response syndrome associated with immune tolerance or suppression.
Resumen de: US20260272995A1
Salmonella typhimurium comprising a first heterologous nucleic acid encoding a first polypeptide that causes bacterial lysis, a second heterologous nucleic acid encoding a second polypeptide that causes vacuolar lysis, and a third heterologous nucleic acid encoding a virus.
Resumen de: US20260276636A1
A method for specifically, rapidly and quantitatively detecting the total viable bacterial count in raw milk, comprises adding a fluorescent probe specific for viable bacteria, a reagent regulating bacterial cell division and a treatment solution to raw milk for a labeling reaction to obtain an initial labeled sample; and detecting particle fluorescent signal in the initial labeled sample using a high-resolution flow cytometer to achieve rapid quantitative detection of the total viable bacterial count; and the total viable bacterial count detected has a good linear correlation with that detected by the traditional plate counting method. The method for rapidly detecting the total viable bacterial count in raw milk can specifically label the viable bacteria in raw milk without being interfered by other biological cells, and the growth activity of the labeled bacteria can be accurately traced to the results of the plate counting method.
Resumen de: US20260274929A1
The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.
Resumen de: WO2025151964A1
One drawback for using attenuated bacteria in cancer therapy and as vaccine vectors faces several challenges. These include ensuring safety and stability of the attenuated strains, achieving consistent colonization or delivery to the target site, and eliciting a controlled immune response. To address this, the present disclosure relates to systems, methods and genetically modified bacteria having reduced risk of reversing virulence without use of antibiotic markers. For example, the genetically modified bacteria comprises a chromosomal disruption in an auxotrophic gene and in one or more gene(s) involved in phosphate regulation, and a DNA rescue molecule comprising a functional copy of the auxotrophic gene. The genetically modified bacteria are obtained from virulent pathogenic bacteria containing a virulence plasmid.
Resumen de: EP4806992A1
0001 Cyclic dinucleotides, which are a type of signaling substance for cancer treatment, are secondary messengers of intracellular events initiated by GPCR activation and act as a stimulator of interferon genes (STING), and thus can have a significant effect on tumor suppression. Meanwhile, when cancer occurs in a subject, angiogenesis and cell growth proceed at a very high rate in the body, and thus an oxygen-deficient environment is created due to incomplete angiogenesis in cancer tissues, which may be very suitable for the proliferation of anaerobic bacteria such as Salmonella sp. strains or E. coli. 0002 Therefore, the present invention relates to a DNA construct into which is introduced a gene for an enzyme that synthesizes a signaling substance for cancer treatment, e.g., a cyclic dinucleotide, or to a strain transformed with a vector comprising the DNA construct. The DNA construct or the strain transformed with a vector comprising the DNA construct, according to the present invention, targets cancer in a subject and then secretes C-di-AMP or C-di-GMP synthase in the surrounding environment of the cancer, and thus can very effectively prevent or treat cancer and, at the same time, can diagnose cancer in real time.
Resumen de: CN122749776A
本发明公开了一种抗沙门菌多表位融合蛋白及其制备方法和应用。本发明的多表位蛋白及其蛋白作为疫苗SEMV能够同时激活Th1、Th2和Th17型免疫应答，诱导高滴度特异性抗体产生和淋巴细胞增殖，对肠炎沙门菌和鼠伤寒沙门菌均具有交叉保护效力。该蛋白及其制备的疫苗具有安全性高、成分明确、无排毒返强风险等优势，可用于预防禽沙门菌感染。
Resumen de: CN122727021A
本发明属于兽用生物制品技术领域，涉及一种沙门氏菌灭活疫苗的梯度灭活制备方法及其应用。该方法包括菌株培养、梯度灭活、灭活检验、抗原浓缩与乳化等步骤，其中梯度灭活包括：第一阶段向菌液中加入终浓度为0.01%～0.10%的甲醛，于2～8℃条件下处理24～72 h；第二阶段补加甲醛至终浓度为0.10%～0.40%，并升温至30～40℃继续处理12～48 h。所述低温低浓度处理用于对菌体表面抗原表位进行预固定，从而减少后续高浓度甲醛处理对抗原结构的破坏。采用本发明方法制备的灭活疫苗在保证灭活彻底性和生物安全性的同时，可显著提高血清抗体水平及肠道黏膜sIgA水平，适用于鸡、鹅等禽类动物沙门氏菌病的预防。
Resumen de: US20260265313A1
The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.
Nº publicación: WO2026185450A1 10/09/2026
Solicitante:
UNIV AUT\u00D2NOMA DE BARCELONA [ES]
UNIVERSITAT AUT\u00D2NOMA DE BARCELONA
Resumen de: WO2026185450A1
Novel antibody for antimicrobial resistance detection Antibodies or fragments thereof are provided that specifically bind to bacterial ribosomal subunit S16 and are useful for capturing RNA of a wide-spectrum of bacteria, thereby improving accuracy and speed of antibiotic resistance diagnostics. The antibody or the fragment thereof comprises a heavy-chain variable region CDR1 comprising the amino acid sequence AMS, a heavy-chain variable region CDR2 comprising SEQ ID NO: 16, a heavy-chain variable region CDR3 comprising SEQ ID NO: 18, a light-chain variable region CDR1 comprising SEQ ID NO: 36, a light-chain variable region CDR2 comprising SEQ ID NO: 38 and a light-chain variable region CDR3 comprising SEQ ID NO: 40.
BOPI
Sede Electrónica
